Dowling & Yahnke LLC Avidity Biosciences, Inc. Transaction History
Dowling & Yahnke LLC
- $215 Million
- Q3 2022
A detailed history of Dowling & Yahnke LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Dowling & Yahnke LLC holds 10,691 shares of RNA stock, worth $452,550. This represents 0.08% of its overall portfolio holdings.
Number of Shares
10,691
Previous 11,281
5.23%
Holding current value
$452,550
Previous $164,000
6.71%
% of portfolio
0.08%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding RNA
# of Institutions
206Shares Held
95.5MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$462 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$373 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$365 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$275 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$252 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.21B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...